SOTIO Expands ADC Pipeline with Two Bispecific Candidates, SOT112 and SOT113

SOTIO Expands ADC Pipeline with Two Bispecific Candidates, SOT112 and SOT113

SOTIO Expands ADC Pipeline with Bispecific Candidates SOT112 and SOT113 SOTIO Biotech Advances Two Promising Bispecific Antibody-Drug Conjugate Programs SOTIO Biotech, a clinical-stage biopharmaceutical company owned by PPF Group, has announced an exciting development in its collaboration with Synaffix B.V.,…

Read MoreSOTIO Expands ADC Pipeline with Two Bispecific Candidates, SOT112 and SOT113
Murata Manufacturing Launches Mass Production of World's First Metal Cell Filter, 'CELLNETTA

Murata Manufacturing Launches Mass Production of World’s First Metal Cell Filter, ‘CELLNETTA’

Murata Manufacturing Unveils the World’s First Metal Cell Filter, “CELLNETTA,” for Efficient Cell Separation Murata Manufacturing Co., Ltd., a global leader in electronic components, has announced the commercialization of the world’s first metallic cell filter, CELLNETTA, a revolutionary product designed…

Read MoreMurata Manufacturing Launches Mass Production of World’s First Metal Cell Filter, ‘CELLNETTA’

Baszucki Group Launches Two Research Initiatives for Youth with Bipolar Disorder

Baszucki Group Launches Two Initiatives Exploring Ketogenic Therapy for Youth with Bipolar Disorder Baszucki Group has announced the launch of two innovative research initiatives aimed at exploring the effectiveness of ketogenic therapy for children and adolescents with bipolar disorder. These…

Read MoreBaszucki Group Launches Two Research Initiatives for Youth with Bipolar Disorder
SCORPIO-PEP Phase 3 Ensitrelvir First Oral Antiviral to Prevent COVID-19

SCORPIO-PEP Phase 3: Ensitrelvir First Oral Antiviral to Prevent COVID-19 as Post-Exposure Prophylaxis

Ensitrelvir Demonstrates Effectiveness in Preventing COVID-19 as Post-Exposure Prophylaxis: Results from the SCORPIO-PEP Phase 3 Trial SCORPIO-PEP Phase 3: Ensitrelvir First Oral Antiviral to Prevent COVID-19 as Post-Exposure Prophylaxis At the Conference on Retroviruses and Opportunistic Infections 2025, Shionogi &…

Read MoreSCORPIO-PEP Phase 3: Ensitrelvir First Oral Antiviral to Prevent COVID-19 as Post-Exposure Prophylaxis
Oligomerix Publishes Preclinical Results of Oral Alzheimer's Drug Study

Oligomerix Publishes Preclinical Results of Oral Alzheimer’s Drug Study

Oligomerix Publishes Preclinical Results of Oral Alzheimer’s Drug Study Oligomerix, Inc., a pioneering clinical-stage biotechnology company focused on developing protein self-association inhibitors for Alzheimer’s disease (AD) and related neurodegenerative disorders, has announced the publication of a preclinical study demonstrating the…

Read MoreOligomerix Publishes Preclinical Results of Oral Alzheimer’s Drug Study
InTandem Capital Partners Invests in Clinilabs for Chemical Industry Growth

InTandem Capital Partners Invests in Clinilabs for Chemical Industry Growth

InTandem Capital Partners Invests in Clinilabs to Accelerate CNS Drug and Device Development InTandem Capital Partners, a private equity firm specializing in healthcare services, has announced a strategic partnership with Clinilabs, a global full-service contract research organization (CRO). This collaboration…

Read MoreInTandem Capital Partners Invests in Clinilabs for Chemical Industry Growth